<DOC>
	<DOCNO>NCT01252095</DOCNO>
	<brief_summary>This first-in-human study aim establish maximum tolerate dose PG545 evaluate safety subject advance solid tumour . In addition study explore whether PG545 exposure result change chemical produce body associated cancer growth spread .</brief_summary>
	<brief_title>Study Safety Tolerability PG545 Patients With Advanced Solid Tumours</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<criteria>Age &gt; =18 year . Histological cytological documentation non hematologic , malignant solid tumour . Have fail least one previous therapeutic regimen . Measurable disease accord RECIST 1.1 . Life expectancy &gt; = 12 week ECOG Performance Status 0 1 Written , sign date informed consent Able willing meet protocolrequired treatment , investigation visit . Have adequate organ function Clinically significant nonmalignant disease . Active CNS metastasis . Subjects uncontrolled diabetes . History clinically significant adverse drug reaction heparin anticoagulant agent History immunemediated thrombocytopaenia platelet abnormality hereditary acquire coagulopathies . Concomitant use aspirin ( &gt; 150 mg/day ) , NSAIDs ( except COX2 selective inhibitor ) , vitamin K antagonist ( lowdose prophylactic use ) , heparin within two week prior randomisation , antiplatelet drug . History severe allergic , anaphylactic significant adverse reaction radiographic contrast medium Known seropositivity human immunodeficiency virus ( HIV ) Women pregnant breastfeeding . Women childbearing potential male subject partner woman childbearing potential unable unwilling practice highly effective mean contraception . Active substance abuse Subjects receive investigational agent within 28 day prior Cycle 1 Day 1 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>PG545</keyword>
	<keyword>Phase I</keyword>
	<keyword>Progen</keyword>
	<keyword>antimetastatic</keyword>
	<keyword>antiangiogenic</keyword>
	<keyword>advanced cancer patient</keyword>
	<keyword>solid tumor</keyword>
	<keyword>solid tumour</keyword>
</DOC>